What is claimed is:

1. A flavonoid polyphenol drug self-emulsifying composition, comprising a flavonoid polyphenol drug-phospholipid complex, an oil phase, an emulsifier and a co-emulsifier, wherein the flavonoid polyphenol drug ~~comprises one or more selected from the group consisting of baicalein, proanthocyanidin, quercetin, curcumin and resveratrol~~is baicalein;

~~optionally, the flavonoid polyphenol drug further comprise other flavonoid polyphenol drugs in addition to baicalein, proanthocyanidin, quercetin, curcumin and resveratrol, wherein the other flavonoid polyphenol drugs are one or more selected from the group consisting of wogonin, ferulic acid, catechin, magnolol, honokiol, apigenin, hesperetin, rotenone, isobavachalcone, aureusidin, delphinidin and ginkgetin;~~

~~optionally, the flavonoid polyphenol drugs are baicalein, proanthocyanidin, quercetin, curcumin or resveratrol;~~

~~optionally, the~~wherein the co-emulsifier is diethylene glycol monoethyl ether and/or propylene glycol monocaprylate.

2. The flavonoid polyphenol drug self-emulsifying composition according to claim 1, wherein the flavonoid polyphenol drug self-emulsifying composition has a drug loading of 10–110 mg/g~~, preferably 10~~.

3. The flavonoid polyphenol drug self-emulsifying composition according to claim 2, wherein the flavonoid polyphenol drug self-emulsifying composition has a drug loading of 10–100 mg/g~~;~~.

~~optionally,~~4. The flavonoid polyphenol drug self-emulsifying composition according to claim 1, wherein the flavonoid polyphenol drug self-emulsifying composition has a particle size of 10–1000 nm.

~~2~~5. The flavonoid polyphenol drug self-emulsifying composition according to claim 1, wherein in the flavonoid polyphenol drug-phospholipid complex, a mass ratio of the flavonoid polyphenol drug to phospholipid is ~~1:1–1:15, optionally,~~ 1:1–1:8.

~~3~~6. The flavonoid polyphenol drug self-emulsifying composition according to ~~claim~~any one of claims 1 ~~or 2~~to 5, wherein the phospholipids are one or more selected from the group consisting of natural phospholipids and synthetic phospholipids;

~~optionally~~wherein, the natural phospholipids comprise one or more selected from the group consisting of soybean phospholipid and egg-yolk phospholipid; and

~~optionally, the~~ the synthetic phospholipids comprise one or more selected from the group consisting of phosphoglyceride, sphingomyelin, phosphatidylcholine, phosphatidylethanolamine, phosphatidyl serine, phosphatidylinositol, phosphatidyl glycerol, glycerophosphatidic acid, distearyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, dipalmitoyl phosphatidylethanolamine and dimyristoyl phosphatidylcholine; preferably, the synthetic phospholipids are one or more selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol and glycerophosphatidic acid.

~~4~~7. The flavonoid polyphenol drug self-emulsifying composition according to any one of claims 1 to ~~3~~6, wherein the oil phase is one or more selected from the group consisting of vegetable oils and vegetable oil derivatives;

~~optionally~~wherein, the vegetable oils comprise one or more selected from the group consisting of soybean oil, corn oil, olive oil, coconut oil, peanut oil, camellia oil and castor oil; and

~~optionally, the~~ the vegetable oil derivatives comprise one or more selected from the group consisting of sorbitan oleate, glyceryl oleate, glyceryl linoleate, polyethylene glycol glyceryl oleate, glycerol monolinoleate, ethyl oleate, ethyl linoleate, C8/C10 monoglyceride, coconut oil C8/C10 diglyceride, coconut oil C8/C10 triglyceride, caprylic acid triglyceride, caprylic acid diglyceride, caprylic acid monoglyceride, capric acid monoglyceride, capric acid diglyceride, capric acid triglyceride, caprylic capric monoglyceride, caprylic capric glyceride, caprylic capric triglyceride, isopropyl myristate, polyethylene glycol glyceryl linoleate, polyethylene glycol glyceryl laurate and propylene glycol monocaprylate~~;~~.

~~preferably,~~8. The flavonoid polyphenol drug self-emulsifying composition according claim 7, wherein the oil phase is one or more selected from the group consisting of soybean oil, castor oil, ethyl oleate, isopropyl myristate and caprylic capric glyceride.

~~5~~9. The flavonoid polyphenol drug self-emulsifying composition according to any one of claims 1 to ~~4~~8, wherein the emulsifier is one or more selected from the group consisting of caprylic capric polyethylene glycol glyceride, polyethylene glycol, Tween, Span 80, polyethylene glycol glyceryl oleate, polyethylene glycol glyceryl linoleate, phospholipids, octyl phenyl polyoxyethylene ether~~;~~.

~~preferably,~~10. The flavonoid polyphenol drug self-emulsifying composition according claim 9,

wherein the emulsifier is one or more of caprylic capric polyethylene glycol glyceride, Tween 80, Tween 85, octyl phenyl polyoxyethylene ether, polyethylene glycol glyceryl oleate.

~~6~~11. The flavonoid polyphenol drug self-emulsifying composition according to any one of claims 1 to ~~5~~10, wherein based on a total mass ratio of the ~~co-~~oil phase, the emulsifier ~~is one or more selected from the group consisting of ethanol, propylene glycol, propylene carbonate, ethylene glycol monoethyl ether, glycerol furfural, dimethyl isosorbide, propylene glycol monocaprylate, diethylene glycol monoethyl ether, polyethylene glycol, glycerol, caprylic capric polyethylene glycol glyceride~~ and ~~benzyl alcohol;~~

~~preferably,~~ the co-emulsifier ~~is one or more of diethylene glycol monoethyl ether, polyethylene glycol 400, ethanol and propylene glycol monocaprylate.~~being 100%, the oil phase accounts for 10–50%, the emulsifier accounts for 30–60%, and the co-emulsifier accounts for 20–60%.

~~7~~12. The flavonoid polyphenol drug self-emulsifying composition according to ~~any one of claims 1 to 6~~claim 11, wherein based on a total mass ratio of the oil phase ~~being 100%,~~ the emulsifier and the co-emulsifier~~,~~ being 100%, the oil phase accounts for ~~10–50% (preferably~~ 20–40%~~),~~%, the emulsifier accounts for ~~30–60% (preferably~~ 40–60%~~),~~%, and the co-emulsifier accounts for ~~20–60% (~~preferably 30–50%~~)~~.

~~8~~13. A method for preparing the flavonoid polyphenol drug self-emulsifying composition according to any one of claims 1 to ~~7~~12, comprising the following preparation steps:

(1) a flavonoid polyphenol drug-phospholipid complex is prepared: flavonoid polyphenol drug and phospholipid are dissolved in an organic solvent, subjected to a compound reaction, and dried with the organic solvent removed so that the flavonoid polyphenol drug-phospholipid complex is obtained;

~~optionally, the organic solvent is one or more selected from the group consisting of ethyl acetate, tetrahydrofuran, methanol, acetone, ethanol, absolute ethanol, n-propanol, isopropanol, n-butanol, isobutanol, tert-butanol, diethyl ether, methyl ethyl ether, dioxane, butanone, petroleum ether, hexane, cyclohexane, dichloromethane, chloroform, carbon tetrachloride, DMSO and DMF, preferably one or more of ethyl acetate, tetrahydrofuran, methanol, ethanol, cyclohexane, DMSO and DMF;~~

(2) the flavonoid polyphenol drug self-emulsifying composition is prepared: the flavonoid polyphenol drug-phospholipid complex obtained in step (1) is fully mixed with an oil phase, an emulsifier and a co-emulsifier in any sequence~~;~~.

~~optionally,~~14. The method according to claim 13, wherein in step (2): the flavonoid polyphenol drug-phospholipid complex obtained in step (1) is fully mixed with the oil phase, the emulsifier and the co-emulsifier directly; or

the oil phase, the emulsifier and the co-emulsifier are mixed uniformly so that a blank self-emulsifying concentrate is prepared, and then the flavonoid polyphenol drug-phospholipid complex obtained in step (1) is added to the prepared blank self-emulsifying concentrate and fully mixed therewith; or

the flavonoid polyphenol drug-phospholipid complex obtained in step (1) is dissolved in any one of the oil phase, the emulsifier or the co-emulsifier, and then the other two of the oil phase, the emulsifier or the co-emulsifier are added and fully mixed.

~~9~~15. The method according to claim 13, wherein the organic solvent is one or more selected from the group consisting of ethyl acetate, tetrahydrofuran, methanol, acetone, ethanol, absolute ethanol, n-propanol, isopropanol, n-butanol, isobutanol, tert-butanol, diethyl ether, methyl ethyl ether, dioxane, butanone, petroleum ether, hexane, cyclohexane, dichloromethane, chloroform, carbon tetrachloride, DMSO and DMF, preferably one or more of ethyl acetate, tetrahydrofuran, methanol, ethanol, cyclohexane, DMSO and DMF.

16. A pharmaceutical composition, comprising the flavonoid polyphenol drug self-emulsifying composition according to any one of claims 1 to ~~7~~12 and an optional pharmaceutically acceptable excipient~~;~~.

~~optionally,~~17. The pharmaceutical composition according to claim 16, wherein a dosage form of the pharmaceutical composition comprises an oral preparation, an injection preparation, a transdermal administration preparation, a mucosal administration preparation, a pulmonary inhalation administration preparation or an enteral administration preparation~~;~~.

~~optionally,~~18. The pharmaceutical composition according to claim 17, wherein the dosage form of the pharmaceutical composition comprises drops, oral liquids, tablets, capsules, granules, infusion granules, films, gel, powders, emulsions, dripping pills, suppositories, aerosols, sprays, powder aerosols, patches, adhesive plasters, solutions, ointments or cream.

~~10~~19. A use of the flavonoid polyphenol drug self-emulsifying composition according to any one of claims 1 to ~~7~~12 or the pharmaceutical composition according to ~~claim 9~~any one of claims 16 to 18 for preparing drugs for anti-bacteria, antivirus, anti-inflammation, inhibiting allergy, regulating immunity, anti-tumor, anti-oxidation, anti-aging, anti-ultraviolet radiation, treatment of hormone deficiency, anti-hypertension, lowering blood fat, anti-atherosclerosis, anti-senile

dementia, treatment of hand-foot-mouth diseases, anti-osteoporosis or liver protection.